Platelet News and Research

RSS

Dual antiplatelet therapy for minor or a warning stroke is underused especially among women

Despite evidence that starting two blood-thinning medications shortly after a minor stroke or a warning stroke (transient ischemic attack - TIA) may prevent a second – possibly more serious – clot-caused stroke within a few months, the treatment regimen is underused especially among women, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2023.

2 Feb 2023

A baby spent 36 days in an in-network NICU. Why did the hospital next door send a bill?

Brenna Kearney was seven months pregnant in December 2019 when she experienced what she thought were bad flu symptoms.

30 Jan 2023

What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?

A recent Eurosurveillance study focused on estimating the incidence of a prespecified list of adverse events following the first and second doses of the COVID-19 vaccination.

23 Jan 2023

Study suggests Alzheimer’s disease diagnosis is associated with higher levels of soluble ACE2 in the human brain

Researchers investigated ACE2 (angiotensin-converting enzyme 2) levels among individuals with AD (Alzheimer’s disease).

23 Jan 2023

Long-term, COVID-19-related smell loss could be treated using injections of platelet-rich plasma

Early in the pandemic, when people with COVID-19 began reporting that they lost their sense of smell, Zara Patel, MD, figured as much. A professor of otolaryngology at Stanford Medicine, Patel has, for years, studied loss of smell as a symptom of viral infections.

19 Jan 2023

How does the brain change with age?

Researchers discussed cellular hallmarks of brain aging and therapeutic interventions to rejuvenate cognitive brain functions.

19 Jan 2023

What are the major findings of long COVID research?

Researchers explored existing literature on long coronavirus disease (COVID). They highlighted key immunological findings, similarities with other diseases, symptoms, and associated pathophysiological mechanisms, and diagnostic and therapeutic options, including COVID-19 vaccinations.

17 Jan 2023

Protein secreted from skeletal muscle cells and helps to repair and grow muscles

Scientists from Tokyo Metropolitan University have discovered that a protein called platelet-derived growth factor subunit B (PDGF-B) is continuously secreted from skeletal muscle cells and helps to repair muscles by encouraging myoblasts (muscle stem cells) to proliferate.

16 Jan 2023

The role of omega-3 and omega-6 metabolites during pregnancy

Omega-3 and -6 fatty acids ingested through the diet are metabolized into bioactive compounds that influence inflammation. In a recent the journal Biomedicines study, scientists reviewed the existing literature and summarized their findings related to the role of omega-3 and omega-6 metabolites during pregnancy.

15 Jan 2023

2022: a year in MIS-C research

In a recent review published in Nature Reviews Rheumatology, researchers reviewed existing data on the multisystem inflammatory syndrome in children (or MIS-C).

11 Jan 2023

Clinically relevant biomarker strategies in drug development

In this interview, NewsMedical speaks with Dr. Justin Devine and Dr. Nicholas Woudberg about biomarkers, their importance for drug development as well as the potential they have when it comes to machine learning.

From Synexa Life Sciences BV 9 Jan 2023

Is appropriate initial empirical antimicrobial therapy associated with lower in-hospital mortality in patients with bloodstream infections?

Researchers estimated the association between the receipt of appropriate initial empirical antibiotic treatment and in-hospital death among individuals hospitalized with BSI (bloodstream infections).

6 Jan 2023

Is platelet-rich plasma therapy beneficial in treating chronic respiratory disease?

Researchers conducted a literature review to determine whether platelet-rich plasma therapy could help slow disease progression through lung regeneration in patients with chronic respiratory disease.

4 Jan 2023

New insights into the bioavailability and hepatoxicity risk of neonicotinoids

Researchers quantified the residues of eight neonicotinoids in human bile samples to understand the association between internal neonicotinoid exposure and hepatotoxic outcomes.

4 Jan 2023

Age-related macular degeneration reported to confer higher risk of severe SARS-CoV-2 infection

Recent evidence has emerged to suggest that age-related macular degeneration (AMD) is a clinical risk factor for increased risk for infection and mortality.

3 Jan 2023

Scientists explore efficacy of small molecule drugs against severe COVID-19 in vitro

Researchers evaluated the efficacy of small molecule drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro.

29 Dec 2022

Review on nanoparticles usage for treating thrombosis induced by SARS-CoV-2 infections

Researchers provided an overview of nanomedicine strategies to treat coronavirus disease 2019 (COVID-19)-induced thrombosis.

21 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

Novel drug shows early potential in combating multiple myeloma

A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania's Abramson Cancer Center at the 2022 American Society of Hematology Annual Meeting (Abstract 565).

12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.